6/29/23, 1:34 AM PANORAMIC Pathway Feedback Search Clinical Topics Home Studies PANORAMIC PANORAMIC Disease COVID 19 infection Trial question What is the role of molnupiravir in high-risk vaccinated adults in the community with COVID-19? Study design Multi-center Open label RCT Population Characteristics of study participants 59.0% female N = 25708 41.0% male 25708 patients (15053 female, 10648 male) Inclusion criteria: adult patients with relevant comorbidities with confirmed COVID-19 for 5 days in the community Key exclusion criteria: pregnancy; lactation; receipt of molnupiravir; allergy to molnupiravir Interventions N=12774 molnupiravir (molnupiravir at a dose of 800 mg BID for 5 days plus usual care) N=12934 standard care only (management of symptoms with antipyretics; monoclonal antibodies and antivirals for very high-risk patients) Primary outcome Hospitalizations or death from all causes at day 28 https://web.pathway.md/studies/recy6ziTTYryLDJNE 1/2 6/29/23, 1:34 AM PANORAMIC Pathway 1.0 % 1 1 0.8 % 0.5 % 0.3 % No significant difference 0.0 % Molnupiravir Standard care only No significant difference in hospitalizations or death from all causes at day 28 (1% vs. 1%; OR 1.06, 95% CI 0.81 to 1.41) Secondary outcomes Borderline significant increase in early sustained recovery (32% vs. 23%; OR 1.62, 95% CI 1.53 to 1.72) Borderline significant increase in days to alleviation of all symptoms (4 days vs. 4 days; HR 1.18, 95% CI 1.15 to 1.22) Safety outcomes No significant difference in serious adverse events. Conclusion In adult patients with relevant comorbidities with confirmed COVID-19 for 5 days in the community, molnupiravir was not superior to standard care only with respect to hospitalizations or death from all causes at day 28. Reference Christopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2022 Dec 22;S0140-6736(22)02597-1. Open reference URL https://web.pathway.md/studies/recy6ziTTYryLDJNE 2/2